Amplia has today announced that it has received a Research and Development Tax Incentive Refund of$3,177,718 for the 2023/2024 financial year.
The refund relates to expenditure incurred in research and development associated with the Company’s FAK inhibitors, narmafotinib (AMP945) and AMP886, and are primarily related to the Company’s ongoing Phase 1b/2a clinical trial of narmafotinib in advanced pancreatic cancer patients.
The Australian Government's Research and Development Tax Incentive is a program to encourage businesses to undertake research and development (R&D) activities and provides eligible companies with cash refunds for 43.5-48.5% of eligible expenditure on research and development activities.
Read today’s ASX release here.
